Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2020, Vol. 34 ›› Issue (6): 123-128.doi: 10.6040/j.issn.1673-3770.0.2020.031

Previous Articles     Next Articles

Correlation between high-mobility group box-1 and allergic rhinitis

ZHU ZhengruOveriew,ZHANG XiaobingGuidance   

  1. Department of Otorhinolaryngology & Head and Neck Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Published:2021-01-11

PDF (PC)

220

Abstract: Allergic rhinitis(AR)is a noninfectious inflammatory disease of the nasal mucosa mediated by IgE and characterized by the upregulation of inflammatory mediators and infiltration of inflammatory cells in the nasal mucosa. As a typical warning protein and damage-related model molecule, high-mobility group box-1(HMGB1)plays a variety of roles in mediating inflammatory response, cell migration, and tissue invasion. Currently, studies on HMGB1 and allergic diseases mainly focus on systemic lupus erythematosus, asthma, and atopic dermatitis, whereas the role of HMGB1 in AR is still controversial. This article summarizes the relevant researches on the role of HMGB1 in the pathogenesis of AR.

Key words: High mobility group box-1, Allergic rhinitis, Pathogenesis, Inflammation, Receptor, Signal pathway

CLC Number: 

  • R765.21
[1] 程雷, 钱俊俊, 田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021. CHENG Lei, QIAN Junjun, TIAN Huiqin. Research progresses on allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021.
[2] Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases[J]. Expert Opin Ther Targets, 2018, 22(3): 263-277. doi:10.1080/14728222.2018.1439924.
[3] Fritz G. RAGE: a single receptor fits multiple ligands[J]. Trends Biochem Sci, 2011, 36(12): 625-632. doi:10.1016/j.tibs.2011.08.008.
[4] Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation[J]. J Allergy Clin Immunol, 2014, 134(2): 440-450. doi:10.1016/j.jaci.2013.12.1035.
[5] Huang WF, Zhao HJ, Dong HM, et al. High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway[J]. Int J Mol Med, 2016, 37(5): 1189-1198. doi:10.3892/ijmm.2016.2537.
[6] Zhu XW, Cong JN, Yang B, et al. Association analysis of high-mobility group box-1 protein 1(HMGB1)/toll-like receptor(TLR)4 with nasal interleukins in allergic rhinitis patients[J]. Cytokine, 2020, 126: 154880. doi:10.1016/j.cyto.2019.154880.
[7] Yuan Y, Liu Q, Zhao J, et al. SIRT1 attenuates murine allergic rhinitis by downregulated HMGB 1/TLR4 pathway[J]. Scand J Immunol, 2018, 87(6): e12667. doi:10.1111/sji.12667.
[8] Tang HP, Li TT, Han XL, et al. TLR4 antagonist ameliorates combined allergic rhinitis and asthma syndrome(CARAS)by reducing inflammatory monocytes infiltration in mice model[J]. Int Immunopharmacol, 2019, 73: 254-260. doi:10.1016/j.intimp.2019.05.021.
[9] Shimizu S, Kouzaki H, Kato T, et al. HMGB1-TLR4 signaling contributes to the secretion of interleukin 6 and interleukin 8 by nasal epithelial cells[J]. Am J Rhinol Allergy, 2016, 30(3): 167-172. doi:10.2500/ajra.2016.30.4300.
[10] Jiang Huanhuan, Duan Junyan, Xu Kaihong, et al. Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway[J]. Experimental and therapeutic medicine vol, 2019,18(1): 459-466. doi: 10.3892/etm.2019.7594.
[11] Zhang Han, Yang Nan, Wang Tianyue, et al. Vitamin D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NFκB signaling pathway[J].Molecular Medicine Reportsvol, 2018, 17(2): 2915-2920. doi: 10.3892/mmr.2017.8216.
[12] 陈删. 高迁移率家族蛋白1在小鼠过敏性鼻炎及急性细菌性鼻窦炎中的表达及其意义[D]. 武汉: 华中科技大学, 2016. CHEN Shan. The role of high mobility group box 1 protein in murine allergic rhinitis and acute bacterial rhinosinusitis[D]. Wuhan: Huazhong University of Science and Technology, 2016.
[13] Liang Y, Hou CC, Kong JL, et al. HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2[J]. Mol Cell Biochem, 2015, 405(1/2): 63-71. doi:10.1007/s11010-015-2396-0.
[14] 徐韶飞, 聂晚频, 姚凯, 等. HMGB1促进血管平滑肌细胞增殖与迁移的机制研究[J]. 中国普通外科杂志, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013. XU Shaofei, NIE Wanpin, YAO Kai, et al. Mechanism for HMGB1 in promoting migration and proliferation of vascular smooth muscle cells[J]. Chinese Journal of General Surgery, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013.
[15] 吴欣阳, 朱宏岩, 吴革平. PI3K/PKB通道在肥大细胞介导的过敏性鼻炎中的多重作用[J]. 临床医药文献电子杂志, 2017, 4(72): 14255-14256. doi:10.16281/j.cnki.jocml.2017.72.163.
[16] Zhang YL, You B, Liu XZ, et al. High-mobility group box 1(HMGB1)induces migration of endothelial progenitor cell via receptor for advanced glycation end-products(RAGE)-dependent PI3K/akt/Enos signaling pathway[J]. Med Sci Monit, 2019, 25: 6462-6473. doi:10.12659/MSM.915829.
[17] Lee CC, Lai YT, Chang HT, et al. Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma[J]. Biochem Pharmacol, 2013, 86(7): 940-949. doi:10.1016/j.bcp.2013.08.003.
[18] Chen YC, Statt S, Wu RE, et al. High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells[J]. Sci Rep, 2016, 6: 18815. doi:10.1038/srep18815.
[19] Kim TH, Lee JY, Lee HM, et al. Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distribution of collagen, proteoglycans, and lymphatic Vessels[J]. Clin Exp Allergy, 2010, 40(12): 1742-54. doi: 10.1111/j.1365-2222.2010.03612.x.
[20] Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death[J]. Clin Exp Otorhinolaryngol, 2015, 8(2): 123-128. doi:10.3342/ceo.2015.8.2.123.
[21] 刘阳, 王志斌, 刘争, 等. 高迁移率族蛋白B1在变应性鼻炎中的表达及意义[J]. 中国免疫学杂志, 2010, 26(7): 651-654. LIU Yang, WANG Zhibin, LIU Zheng, et al. doi: CNKI:SUN:ZMXZ.0.2010-07-018. The expression of HMGB1 in nasal mucosa of allergic rhinitis patients and its significance[J]. Chinese Journal of Immunology, 2010, 26(7): 651-654. doi: CNKI:SUN:ZMXZ.0.2010-07-018.
[22] Lu B, Wang C, Wang M, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review[J]. Expert Rev Clin Immunol, 2014, 10(6): 713-727. doi:10.1586/1744666X.2014.909730.
[23] Pellegrini L, Xue JM, Larson D, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma[J]. Oncotarget, 2017, 8(14): 22649-22661. doi:10.18632/oncotarget.15152.
[24] Seo MS, Kim HJ, Kim H, et al. Ethyl pyruvate directly attenuates active secretion of HMGB1 in proximal tubular cells via induction of heme oxygenase-1[J]. J Clin Med, 2019, 8(5): E629. doi:10.3390/jcm8050629.
[25] Liu YY, Chen NH, Chang CH, et al. Ethyl pyruvate attenuates ventilation-induced diaphragm dysfunction through high-mobility group box-1 in a murine endotoxaemia model[J]. J Cell Mol Med, 2019, 23(8): 5679-5691. doi:10.1111/jcmm.14478.
[26] Wagner N, Dieteren S, Franz N, et al. Ethyl pyruvate ameliorates hepatic injury following blunt chest trauma and hemorrhagic shock by reducing local inflammation, NF-kappaB activation and HMGB1 release[J]. PLoS One, 2018, 13(2): e0192171. doi:10.1371/journal.pone.0192171.
[27] Chen S, Wang YJ, Gong GQ, et al. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release[J]. Exp Biol Med(Maywood), 2015, 240(11): 1490-1499. doi:10.1177/1535370214566563.
[28] Bhat SM, Massey N, Karriker LA, et al. Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling[J]. Respir Res, 2019, 20(1): 27. doi:10.1186/s12931-019-0992-3.
[29] Shin JH, Kim ID, Kim SW, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium[J]. Mol Med, 2015, 20: 649-657. doi:10.2119/molmed.2014.00039.
[30] Chen D, Bellussi LM, Cocca S, et al. Glycyrrhetinic acid suppressed hmgb1 release by up-regulation of Sirt6 in nasal inflammation[J]. J Biol Regul Homeost Agents, 2017, 31(2): 269-277.
[31] Bellussi LM, Cocca S, Passali GC, et al. HMGB1 in the pathogenesis of nasal inflammatory diseases and its inhibition as new therapeutic approach: a review from the literature[J]. Int Arch Otorhinolaryngol, 2017, 21(4): 390-398. doi:10.1055/s-0036-1597665.
[1] WANG Xingxin, YANG Xinyu, ZHENG Xiaojun, DING Lin, SHENG Yawen, BI Xiaoyun, YANG Jiguo. Acupoint application therapy for adenoid hypertrophy in children: a case report [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 122-124.
[2] AO Tian,CHENG Lei. An endotype study of chronic rhinosinusitis with nasal polyps and precise control and treatment under the guidance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 7-14.
[3] SHI Shuai, ZHENG Quan,CHENG Lei. Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 36-42.
[4] LIN Hai, ZHU Ying,ZHANG Weitian. The roles of ion channels in the pathogenesis of chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 64-70.
[5] HUANG Danyi, ZHANG Ting,CHEN Jing, ZHANG Wei. Progress of research regarding the role of the epithelial barrier in chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 78-83.
[6] LI Jiani, ZHU Dongdong,MENG Cuida. The role of epigenetics in the pathogenesis of chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 84-91.
[7] NI Jingzi, WAN Wenjin,CHENG Lei. Research progress on health-related quality of life in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 110-115.
[8] LIN Yihang,LI Youjin. Research progress on gut microbiome in children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 116-122.
[9] LIU Zhen,SONG Xicheng. Mechanisms and research progress of pyroptosis in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 123-129.
[10] WANG Na,CHAI Xiangbin. Research progress on prostate-derived ETS factor in asthma and inflammatory diseases of the nasal mucosa [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 136-141.
[11] LIU Yitong, ZHOU Suizi,QIU Qianhui. Research progress on NLRP3 inflammasome in chronic rhinosinusitis and allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 142-146.
[12] GONG Xiaoyang, CHENG Lei. Analysis of proportion of outpatients with allergic rhinitis during the coronavirus infectious disease 2019 pandemic [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 245-255.
[13] ZHANG Yaqi, LIU Huimin, CAO Linman, WANG Ziyu, LIN Xu, LI Yanping, XUE Gang, WU Jingfang. Expression and significance of the MAPK,PI3K-AKT,NF-κB pathways of allergic rhinitis in mice [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 254-259.
[14] LU Weili, JIANG Tao, LI Xianhua. Analysis of sIgE in polysensitized children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 260-265.
[15] HUANG Kaiyue, LI Xueqing, HAN Gouxin, ZHANG Qinxiu. Meta-analysis of acupoint catgut embedding in the treatment of allergic rhinitis based on the theory of “lung and spleen” [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 266-274.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 84 -87 .
[2] NIU Shanli,CHAI Maowen,LI Zhenxiu . Endoscopic rhinoplasty of inferior turbinate in 60 patients with chronic hypertrophic rhinitis[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 16 -18 .
[3] MENG Qing-guo,LU Yong-tian,FAN Xian-liang .

Association of killer cell immunoglobulin-like receptor gene polymorphisms with nasopharyngeal carcinoma

[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 196 -199 .
[4] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 199 -199 .
[5] WAN Li-jia,LU Hai-tao,JIANG Yi-dao,LIU Hui,LI Qin,SHE La-zhi . Effect of H-uvulopalatopharyngoplasty on obstructive sleep apnea
hypopnea syndrome[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 204 -205 .
[6] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 222 -224 .
[7] JI Xiao-bin,DENG Jia-de,ZANG Lin-quan,WANG Lei,XIE Jun . Blood histamine in guinea pigs with allergic rhinitis[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 228 -230 .
[8] XIANG Deng,LU Yong-tian,SUN Huan-ji . Endoscopic repair for cerebrospinal fluid rhinorrhea in 19 cases and a literature review [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 234 -236 .
[9] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 253 -257 .
[10]
YIN Guo-hua,ZHONG Xiao . Long-term effect of laser reduction on lingua adenoids
[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 280 -282 .
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd